Lean Hogs (LH)

Ultime notizie per Labcorp Hldgs (NYSE:LH) Azioni

Labcorp Holdings

Labcorp Hldgs

Laboratory Corp

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Long Ideas

News

Markets

Media

Trading Ideas

Laboratory Corporation Of America Holdings

PENN

UBER

L&#39;esperto del settore finanziario offre preziosi consigli su Uber e altre azioni, valutando potenzialità di crescita e investimenti sicuri.

Il consiglio dell&#39;esperto Jim Cramer su Uber e altri titoli

Personalized medicine, which involves tailoring treatment to a patient&#8217;s unique disease profile, is widely regarded as the holy grail of medicine. However, the current implementation of this approach faces significant hurdles.
Bank of America Securities (BofA) highlights that the precision medicine approach is currently <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">cost, labor, and time-intensive</a>.
Analysts Alec Stranahan and Michael Ryskin specifically point out that the substantial amount of manual work involved in processing complex biological data and making treatment decisions leads to considerable delays.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45820489/goldman-sachs-bullish-on-branded-drug-upside-at-teva-what-about-viatris" rel="noreferrer noopener">Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?</a>
Beyond the practical challenges, precision medicine also grapples with data validation issues. Given the infinitely complex nature of biology and the huge number of interactions between biological systems, researchers often run into issues with validating the impact of genes/pathways associated with disease progression/response to treatment.
Despite these inherent challenges, the integration of Artificial Intelligence (AI) and Machine Learning (ML) is widely recognized as a pivotal enabler for advancing precision medicine.
Consequently, a number of companies are actively leveraging these technologies to innovate within the precision medicine landscape, striving to make tailored treatments more accessible, efficient, and effective.
These companies include Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), Quest Diagnostics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), and LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), each employing AI in unique ways to enhance diagnostics, therapy selection, and overall patient care across the care continuum.
<h2 class="wp-block-heading">Tempus AI</h2>
BofA analyst says Tempus AI perfectly fits the theme of <a target="_blank" href="https://www.benzinga.com/news/movers-shakers/25/06/45726456/tempus-ai-stock-is-surging-today-what-investors-are-watching" rel="noreferrer noopener">AI in precision medicine</a>.
Like most MDx companies, Tempus AI has built its business off an industry-leading database of clinico-genomic data. Tempus leverages this data by training AI/ML algorithms to parse through the data and detect patterns and anomalies.&nbsp;&nbsp;
BofA reiterates a Neutral rating for Tempus AI, given its already premium valuation. The analyst remains constructive on the business and key markets. However, due to peer group expansion, BofA raised its price <a target="_blank" href="https://www.benzinga.com/quote/TEM/analyst-ratings" rel="noreferrer noopener">forecast from $68 to $70</a>.
<h2 class="wp-block-heading">Guardant Health</h2>
Guardant Health was an early mover in the liquid biopsy cancer testing/therapy selection market with their <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45756387/why-is-cancer-diagnostic-guardant-health-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Guardant 360 (G360) test</a>.
Guardant Health has a clear goal to build upon its G360 test (therapy selection) and expand across the care continuum, thus allowing it to participate in a patient&#8217;s receiving precision medicine at all stages post-cancer diagnosis.
Guardant Health has its business built on the algorithms that it runs.
BofA <a target="_blank" href="https://www.benzinga.com/quote/GH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on Guardant Health, given its leading position, strong growth profile, and upcoming catalyst path for new products.
<h2 class="wp-block-heading">Exact Sciences</h2>
BofA analysts say Exact Sciences Corp. has expanded to offer services <a href="https://www.benzinga.com/general/health-care/25/05/45165534/cancer-diagnostic-firm-exact-sciences-ceo-says-strong-q1-paves-way-for-transformative-2025-lifts-annual-guidance" target="_blank" rel="noreferrer noopener">across the care continuum</a>.
While Exact Sciences started screening for colorectal cancer specifically, their focus has been steered towards all indications and across the treatment paradigm.
Exact Sciences&#8217; legacy Cologuard test / early detection doesn&#8217;t necessarily &#8220;fit&#8221; the precision medicine theme; however, everything Exact has done since is &#8220;precision medicine / AI-aligned,&#8221; BofA added in its investor note on Wednesday.
Given its strong financial profile and near-term catalyst path, the analyst maintains a <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Buy rating on Exact Sciences</a>.
<h2 class="wp-block-heading">NeoGenomics</h2>
NeoGenomics has been known as a traditional reference lab offering many hotspot tests. However, by adding the PanTracer testing family and data services offering, NeoGenomics leverages the numerous hotspot data points and can build those into a more robust AI algorithm to inform the more modern therapy selection tests.
The dataset/algorithm and 500+ tests create a flywheel where the tests that are sold generate information. The information informs the algorithm, eventually leading to more accurate algorithms, which help market the tests… bring you back to more tests.
BofA <a target="_blank" href="https://www.benzinga.com/quote/NEO/analyst-ratings" rel="noreferrer noopener">maintains a Neutral rating</a> on NeoGenomics given near-term headwinds and more limited upside versus its prior trajectory.
<h2 class="wp-block-heading">Quest Diagnostics</h2>
Quest Diagnostics is showing trends toward AI in precision medicine with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">Haystack and PathAI Quest</a>.
While not traditionally considered a &#8220;leader&#8221; in AI/precision medicine, Quest Diagnostics has shown progress toward becoming a company to watch.
At DGX&#8217;s 2025 Investor Day, management discussed innovations in lab diagnostics, including the adoption of AI and automation. Given Quest Diagnostics&#8217; strong, steady performance and lower exposure to macro/policy overhangs, the analyst <a target="_blank" href="https://www.benzinga.com/quote/DGX/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a>.
<h2 class="wp-block-heading">LabCorp</h2>
LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) aims to be a notable player in AI precision medicine. Although LabCorp is known as a traditional reference lab, with trends toward AI and precision medicine, LH has shown signs of <a target="_blank" href="https://www.benzinga.com/25/02/43539754/labcorp-reports-q4-earnings-beat-and-expects-strong-2025-growth-analyst-reiterates-outperform-on-stable-2025-outlook" rel="noreferrer noopener">jumping on the bandwagon</a>.
While LabCorp already offers NGS tests, there appears to be a clear trend and focus towards advancing its AI/precision medicine portfolio.
BofA <a target="_blank" href="https://www.benzinga.com/quote/LH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on LabCorp, given strong and steady performance and lower exposure to macro/policy overhangs.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46100456/tesla-robotaxi-scaling-growth-will-be-slow-in-near-term-goldman-sachs" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Scaling Growth Will Be Slow In Near Term: Goldman Sachs</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Analyst Color

Biotech

Health Care

Analyst Ratings

General

EXAS

Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out

Barclays analyst Jack Meehan maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and raises the price target from $250 to $275.

Price Target

Barclays Maintains Equal-Weight on Labcorp Hldgs, Raises Price Target to $275

New offering delivers convenient, comprehensive lab testing solutions for functional medicine, integrative medicine and primary care providers
BURLINGTON, N.C., June 18, 2025 /PRNewswire/ -- Labcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), a global leader of innovative and comprehensive laboratory services, announced today the launch of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4451797-1&amp;h=670611564&amp;u=https%3A%2F%2Fwww.labcorp.com%2Fproviders%2Fwhole-health-solutions&amp;a=Labcorp+Whole+Health+Solutions">Labcorp Whole Health Solutions</a>&nbsp;to support the growing needs of functional medicine, integrative medicine and primary care providers in delivering holistic care. The solution launches specialized test panels and a tailored test menu of more than 1,000 scientifically backed biomarkers for cardiometabolic health, hormones, micronutrients, longevity and whole body wellness.

Labcorp Launches Labcorp Whole Health Solutions To Expand Holistic Care Offerings

On June 12, a recent SEC filing unveiled that Kerrii B Anderson, Board Member at Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) made an insider sell.
What Happened: Anderson opted to sell 500 shares of Labcorp Hldgs, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000920148/000112760225017341//Archives/edgar/data/920148/000112760225017341/0001127602-25-017341-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The transaction's total worth stands at $130,000.
In the Thursday's morning session, Labcorp Hldgs's shares are currently trading at $259.9, experiencing a down of 0.02%.
<h3>Unveiling the Story Behind Labcorp Hldgs</h3>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Hldgs's Financial Performance</h3>
Revenue Growth: Labcorp Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 5.3%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 28.34%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.54, Labcorp Hldgs showcases strong earnings per share.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.78, Labcorp Hldgs faces challenges in effectively managing its debt levels, indicating potential financial strain.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 29.98, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.66, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 15.41, Labcorp Hldgs's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000920148">Check Out The Full List Of Labcorp Hldgs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Decision: Kerrii B Anderson Offloads $130K Worth Of Labcorp Hldgs Stock

Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), a global leader of innovative and comprehensive laboratory services.
As part of an ongoing agreement, Predictive Oncology recently developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, including a human and rat model. Both models represent the liver microenvironment and can be used for the evaluation of both drug metabolism and liver toxicity related to drugs.

POAI

Predictive Oncology Develops 3D Organoid Models Exclusively For Labcorp, Including Human And Rat Model

In the preceding three months, 8 analysts have released ratings for Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $270.0, along with a high estimate of $290.00 and a low estimate of $240.00. Marking an increase of 2.61%, the current average surpasses the previous average price target of $263.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1749664864_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Labcorp Hldgs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$267.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$274.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$240.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jamie Clark</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$276.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Labcorp Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Labcorp Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Labcorp Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Delving into Labcorp Hldgs's Background</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Labcorp Hldgs displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 5.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Labcorp Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Labcorp Hldgs's ROE excels beyond industry benchmarks, reaching 2.6%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.18%, the company showcases effective utilization of assets.
Debt Management: Labcorp Hldgs's debt-to-equity ratio surpasses industry norms, standing at 0.78. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About Labcorp Hldgs

Morgan Stanley analyst Ricky Goldwasser maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Overweight and raises the price target from $270 to $283.

Morgan Stanley Maintains Overweight on Labcorp Hldgs, Raises Price Target to $283

Labcorp Expands Oncology Portfolio With New Tests For Solid And Blood Cancers; Reveals Expansion Of Capabilities To OmniSeq INSIGHT

Truist Securities analyst David Macdonald maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $274 to $290.

Truist Securities Maintains Buy on Labcorp Hldgs, Raises Price Target to $290

Ratings for Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Labcorp Hldgs and provided 12-month price targets. The average target is $269.7, accompanied by a high estimate of $300.00 and a low estimate of $240.00. Observing a 4.0% increase, the current average has risen from the previous average price target of $259.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1746554439_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Labcorp Hldgs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$267.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$274.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$240.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jamie Clark</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$276.00</td>
<td>-</td>
</tr>
<tr>
<td>Ralph Giacobbe</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Labcorp Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Labcorp Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Labcorp Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Delving into Labcorp Hldgs's Background</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Understanding the Numbers: Labcorp Hldgs's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Labcorp Hldgs's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 5.3%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Labcorp Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 6.36%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Labcorp Hldgs's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.6%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Labcorp Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of 1.18%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Labcorp Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.78, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Labcorp Hldgs's Future

Piper Sandler analyst David Westenberg maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Neutral and raises the price target from $260 to $280.

Piper Sandler Maintains Neutral on Labcorp Hldgs, Raises Price Target to $280

Barclays analyst Jack Meehan maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and raises the price target from $240 to $250.

Barclays Maintains Equal-Weight on Labcorp Hldgs, Raises Price Target to $250

Baird analyst Eric Coldwell maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and raises the price target from $253 to $267.

Baird Maintains Outperform on Labcorp Hldgs, Raises Price Target to $267

Wall Street rose modestly by midday Tuesday, as investors weighed the latest developments in trade negotiations and awaited a wave of key economic data and corporate earnings set for <a href="https://www.benzinga.com/25/04/45072497/us-trade-deficit-explodes-to-record-162-billion-in-march-as-import-frenzy-precedes-trumps-tariff-barrage">release later this week.</a>
President Donald Trump is <a href="https://apnews.com/article/trump-tariffs-automakers-factories-relief-25a400c98e02c01c8c54502384e267e1">expected</a> to unveil a new executive order on auto tariffs later today. Meanwhile, U.S. Treasury Secretary Bessent added that the administration is pursuing bilateral trade agreements with 17 major partners, excluding China.
The S&amp;P 500 climbed 0.4%, putting it on track for a sixth consecutive gain—its longest winning streak since November 2024.
In the bond market, U.S. Treasuries extended their rally, with yields falling for a sixth straight session. The yield on the 10-year benchmark dropped to 4.17%, marking a two-week low.
Gold prices slipped 0.6% to $3,325 per ounce, while WTI crude oil futures fell 2.4% to $60 per barrel, the lowest level in two weeks. Oil prices are under pressure from escalating global trade tensions and weaker U.S. economic data, and crude is now on track for a 15% decline in April—its steepest monthly drop since 2021.
Bitcoin traded little changed, around $95,000.
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,513.32</td>
<td>+285.73</td>
<td>0.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,548.89</td>
<td>+20.14</td>
<td>0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,468.38</td>
<td>+41.09</td>
<td>0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,969.38</td>
<td>+3.83</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.4% up to $552.91.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.7% to $404.9.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;edged 0.3% higher to $473.78.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.5% to $195.96.</li>
<li>The&nbsp;Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 0.8%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
Stocks moving on earnings report included:
<ul>
<li>Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>): down 0.6%</li>
<li>Cadence Design Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>): up 4.0%</li>
<li>Brown &amp; Brown, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>): down 6.3%</li>
<li>Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>): up 0.9%</li>
<li>F5 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>): down 0.9%</li>
<li>Alexandria Real Estate Equities Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>): down 6.7%</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>): down 1.0%</li>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>): up 2.7%</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>): up 5.0%</li>
<li>American Tower Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>): up 4.3%</li>
<li>Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>): up 5.2%</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>): down 7.7%</li>
<li>Zebra Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>): up 6.1%</li>
<li>Ecolab, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>): up 2.2%</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>): up 1.6%</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>): up 2.3%</li>
<li>Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>): down 1.6%</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>): down 0.5%</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>): down 0.7%</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): up 1.9%</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): up 4.4%</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): up 0.8%</li>
<li>Sysco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>): up 0.4%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>): up 1.5%</li>
<li>Incyte Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>): up 1.5%</li>
<li>Altria Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>): up 0.7%</li>
<li>Corning, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>): up 2.5%</li>
<li>Paccar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>): down 3.0%</li>
<li>A.O. Smith Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>): up 4.0%</li>
<li>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>): up 0.5%</li>
<li>Entergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): down 1.4%</li>
</ul>
Stocks slated to report earnings after the bell include Arch Capital Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Caesars Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>), Veralto Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>), Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Extendicare Inc. (TSE: EXE), Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Boston Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>), PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>), Extra Space Storage Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>), Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>), ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), CoStar Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>), Regency Centers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>), and Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>).
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Economics

ETFs

ACGL

BKNG

CDNS

CSGP

SPDR Dow Jones Industrial Average ETF Trust

FFIV

FICO

FSLR

INCY

MDLZ

PCAR

PYPL

REGN

SBUX

SPGI

VLTO

Select Sector SPDR-Consumer Discretionary

ZBRA

Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?

<ul>
<li>Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS:
<ul>
<li>Revenue guidance of 6.7% to 8.0%</li>
<li>Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05</li>
<li>Free Cash Flow of $1.10 billion to $1.25 billion</li>
</ul>
</li>
</ul>

Guidance

Labcorp Raises FY25 Adj EPS Guidance From $15.60-$16.40 To $15.70-$16.40 Vs $17.59 Estimate; Reaffirms Sales Guidance Of $13.88B-$14.05B Vs $14.58B Estimate

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported quarterly earnings of $3.84 per share which missed the analyst consensus estimate of $4.17 by 7.91 percent. This is a 4.35 percent increase over earnings of $3.68 per share from the same period last year. The company reported quarterly sales of $3.35 billion which missed the analyst consensus estimate of $3.48 billion by 3.93 percent. This is a 5.29 percent increase over sales of $3.18 billion the same period last year.

Earnings

Earnings Misses

Laboratory Corp Q1 Adj. EPS $3.84 Misses $4.17 Estimate, Sales $3.35B Miss $3.48B Estimate

AEYE

AMSF

APAM

ARCB

ARCC

ASTE

ASTL

ATRC

BBIO

BBVA

BGFV

BRSP

CECO

CHCT

CLVT

CVLT

DHIL

ENSG

ENVA

ESRT

ETWO

EXLS

FELE

FFIC

FIBK

FOUR

FRSH

FRST

FYBR

HLMN

HOUS

HRZN

HSBC

HURN

ILPT

INTZ

JAKK

JBGS

JBLU

KNSA

LFUS

LGIH

LOGI

LXFR

Earnings Scheduled For April 29, 2025

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Laboratory Corp will report an earnings per share (EPS) of $3.73. 
Anticipation surrounds Laboratory Corp's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.06, leading to a 0.59% drop in the share price the following trading session.
Here's a look at Laboratory Corp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.39</td>
<td>3.49</td>
<td>3.78</td>
<td>3.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.45</td>
<td>3.50</td>
<td>3.94</td>
<td>3.68</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856181_0.png" alt="eps graph" />
<h3>Performance of Laboratory Corp Shares</h3>
Shares of Laboratory Corp were trading at $228.31 as of April 25. Over the last 52-week period, shares are up 13.57%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Laboratory Corp</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Laboratory Corp.
The consensus rating for Laboratory Corp is Buy, derived from 9 analyst ratings. An average one-year price target of $273.0 implies a potential 19.57% upside.
<h3>Peer Ratings Comparison</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Quest Diagnostics, DaVita and Chemed, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Quest Diagnostics, with an average 1-year price target of $183.86, suggesting a potential 19.47% downside.</li>
<li>Analysts currently favor an Neutral trajectory for DaVita, with an average 1-year price target of $169.0, suggesting a potential 25.98% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Chemed, with an average 1-year price target of $670.5, suggesting a potential 193.68% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Quest Diagnostics, DaVita and Chemed, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labcorp Hldgs</td>
<td>Buy</td>
<td>9.76%</td>
<td>$896.30M</td>
<td>1.77%</td>
</tr>
<tr>
<td>Quest Diagnostics</td>
<td>Neutral</td>
<td>12.09%</td>
<td>$863M</td>
<td>3.20%</td>
</tr>
<tr>
<td>DaVita</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$1.07B</td>
<td>102.13%</td>
</tr>
<tr>
<td>Chemed</td>
<td>Outperform</td>
<td>1.09%</td>
<td>$234.12M</td>
<td>6.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Laboratory Corp ranks highest in gross profit among its peers. It is in the middle for consensus rating and revenue growth. However, it has the lowest return on equity compared to the other companies analyzed.
<h3>Get to Know Laboratory Corp Better</h3>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Laboratory Corp's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Laboratory Corp showcased positive performance, achieving a revenue growth rate of 9.76% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Laboratory Corp's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Laboratory Corp's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.77%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Laboratory Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.78%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Laboratory Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/LH/earnings">To track all earnings releases for Laboratory Corp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Laboratory Corp

Labcorp Announced Today The Expansion Of Its Precision Oncology Portfolio With Two Solutions

Acquisition aims to provide broader access to comprehensive testing and laboratory services for patients and physicians in North Mississippi &nbsp;
BURLINGTON, N.C. (April 21, 2025) –&nbsp;<a href="https://www.labcorp.com/">Labcorp</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>),&nbsp;a global leader of innovative and comprehensive laboratory services, and North Mississippi Health Services announced today that Labcorp has completed its acquisition of North Mississippi Health Services' ambulatory outreach laboratory business and become a referral laboratory for its seven hospitals and clinic laboratories. &nbsp; Through this acquisition, North Mississippi Health Services' patients and providers will have continuity of high-quality laboratory services and access to Labcorp's leading clinical laboratory services, robust data and digital tools.&nbsp;In addition, Labcorp will open three new patient service centers in Tupelo, West Point and Amory by mid-year to increase availability of laboratory services in North Mississippi.&nbsp;

Reported April 18, 2025: Labcorp Acquires Select Assets Of North Mississippi Health Services' Ambulatory Outreach Laboratory Business; No Financial Terms Disclosed

Press Releases

Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Dividends

Labcorp Declares Quarterly Dividend

Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Labcorp Announces 2025 First Quarter Results

Labcorp to Webcast Its Annual Meeting of Shareholders May 15

SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Labcorp Launches Labcorp Whole Health Solutions to Support Holistic Care

Labcorp to Announce Second Quarter Financial Results on July 24, 2025

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Labcorp Hldgs

Notizie

Ultime notizie per Labcorp Hldgs (NYSE:LH) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO